TNFRSF17 and plasma cell myeloma: We investigated, in our ex vivo BM assay, combination treatment of multiple myeloma with allogeneic anti-BCMA CAR T cells and a GSI in an attempt to transiently increase BCMA expression at the cell surface of multiple myeloma cells and make them more amenable to targeting by CAR T cells.